The clinical study NCT01504854, also called the “Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients with Mild to Moderate AD,” was undertaken in 2011 to evaluate the effectiveness of resveratrol for changing AD CSF biomarkers (total tau, Aβ42, Aβ40, and phospho-tau181), the effect of resveratrol treatment on hippocampal atrophy and regional cortical thinning, and the influence of resveratrol administration on the outcomes of several clinical scales used to assess the severity of dementia [233]. Here, MAPT is linked to Alzheimer disease.